287 related articles for article (PubMed ID: 28007570)
1. Dysfunctional oleoylethanolamide signaling in a mouse model of Prader-Willi syndrome.
Igarashi M; Narayanaswami V; Kimonis V; Galassetti PM; Oveisi F; Jung KM; Piomelli D
Pharmacol Res; 2017 Mar; 117():75-81. PubMed ID: 28007570
[TBL] [Abstract][Full Text] [Related]
2. Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome.
Knani I; Earley BJ; Udi S; Nemirovski A; Hadar R; Gammal A; Cinar R; Hirsch HJ; Pollak Y; Gross I; Eldar-Geva T; Reyes-Capo DP; Han JC; Haqq AM; Gross-Tsur V; Wevrick R; Tam J
Mol Metab; 2016 Dec; 5(12):1187-1199. PubMed ID: 27900261
[TBL] [Abstract][Full Text] [Related]
3. Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats.
Fu J; Oveisi F; Gaetani S; Lin E; Piomelli D
Neuropharmacology; 2005 Jun; 48(8):1147-53. PubMed ID: 15910890
[TBL] [Abstract][Full Text] [Related]
4. Feeding-induced oleoylethanolamide mobilization is disrupted in the gut of diet-induced obese rodents.
Igarashi M; DiPatrizio NV; Narayanaswami V; Piomelli D
Biochim Biophys Acta; 2015 Sep; 1851(9):1218-26. PubMed ID: 26024927
[TBL] [Abstract][Full Text] [Related]
5. Sleeve gastrectomy leads to weight loss in the Magel2 knockout mouse.
Arble DM; Pressler JW; Sorrell J; Wevrick R; Sandoval DA
Surg Obes Relat Dis; 2016 Dec; 12(10):1795-1802. PubMed ID: 27396546
[TBL] [Abstract][Full Text] [Related]
6. Oleoylethanolamide: The role of a bioactive lipid amide in modulating eating behaviour.
Sihag J; Jones PJH
Obes Rev; 2018 Feb; 19(2):178-197. PubMed ID: 29124885
[TBL] [Abstract][Full Text] [Related]
7. Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain.
Suardíaz M; Estivill-Torrús G; Goicoechea C; Bilbao A; Rodríguez de Fonseca F
Pain; 2007 Dec; 133(1-3):99-110. PubMed ID: 17449181
[TBL] [Abstract][Full Text] [Related]
8. Regulation of food intake by oleoylethanolamide.
Lo Verme J; Gaetani S; Fu J; Oveisi F; Burton K; Piomelli D
Cell Mol Life Sci; 2005 Mar; 62(6):708-16. PubMed ID: 15770421
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of the mouse Magel2 gene results in growth abnormalities similar to Prader-Willi syndrome.
Bischof JM; Stewart CL; Wevrick R
Hum Mol Genet; 2007 Nov; 16(22):2713-9. PubMed ID: 17728320
[TBL] [Abstract][Full Text] [Related]
10. Progressive postnatal decline in leptin sensitivity of arcuate hypothalamic neurons in the Magel2-null mouse model of Prader-Willi syndrome.
Pravdivyi I; Ballanyi K; Colmers WF; Wevrick R
Hum Mol Genet; 2015 Aug; 24(15):4276-83. PubMed ID: 25926624
[TBL] [Abstract][Full Text] [Related]
11. Muscle dysfunction caused by loss of Magel2 in a mouse model of Prader-Willi and Schaaf-Yang syndromes.
Kamaludin AA; Smolarchuk C; Bischof JM; Eggert R; Greer JJ; Ren J; Lee JJ; Yokota T; Berry FB; Wevrick R
Hum Mol Genet; 2016 Sep; 25(17):3798-3809. PubMed ID: 27436578
[TBL] [Abstract][Full Text] [Related]
12. The Prader-Willi syndrome proteins MAGEL2 and necdin regulate leptin receptor cell surface abundance through ubiquitination pathways.
Wijesuriya TM; De Ceuninck L; Masschaele D; Sanderson MR; Carias KV; Tavernier J; Wevrick R
Hum Mol Genet; 2017 Nov; 26(21):4215-4230. PubMed ID: 28973533
[TBL] [Abstract][Full Text] [Related]
13. The lipid messenger OEA links dietary fat intake to satiety.
Schwartz GJ; Fu J; Astarita G; Li X; Gaetani S; Campolongo P; Cuomo V; Piomelli D
Cell Metab; 2008 Oct; 8(4):281-288. PubMed ID: 18840358
[TBL] [Abstract][Full Text] [Related]
14. Oea Signaling Pathways and the Metabolic Benefits of Vertical Sleeve Gastrectomy.
Hutch CR; Trakimas DR; Roelofs K; Pressler J; Sorrell J; Cota D; Obici S; Sandoval DA
Ann Surg; 2020 Mar; 271(3):509-518. PubMed ID: 30702457
[TBL] [Abstract][Full Text] [Related]
15. Role of endocannabinoids and their analogues in obesity and eating disorders.
Gaetani S; Kaye WH; Cuomo V; Piomelli D
Eat Weight Disord; 2008 Sep; 13(3):e42-8. PubMed ID: 19011363
[TBL] [Abstract][Full Text] [Related]
16. Dopamine pathway imbalance in mice lacking Magel2, a Prader-Willi syndrome candidate gene.
Luck C; Vitaterna MH; Wevrick R
Behav Neurosci; 2016 Aug; 130(4):448-59. PubMed ID: 27254754
[TBL] [Abstract][Full Text] [Related]
17. A systematic review of the effects of oleoylethanolamide, a high-affinity endogenous ligand of PPAR-α, on the management and prevention of obesity.
Tutunchi H; Saghafi-Asl M; Ostadrahimi A
Clin Exp Pharmacol Physiol; 2020 Apr; 47(4):543-552. PubMed ID: 31868943
[TBL] [Abstract][Full Text] [Related]
18. Feeding regulation by oleoylethanolamide synthesized from dietary oleic acid.
Igarashi M; Iwasa K; Yoshikawa K
Prostaglandins Leukot Essent Fatty Acids; 2021 Feb; 165():102228. PubMed ID: 33385936
[TBL] [Abstract][Full Text] [Related]
19. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha).
Guzmán M; Lo Verme J; Fu J; Oveisi F; Blázquez C; Piomelli D
J Biol Chem; 2004 Jul; 279(27):27849-54. PubMed ID: 15123613
[TBL] [Abstract][Full Text] [Related]
20. Oleic acid-derived oleoylethanolamide: A nutritional science perspective.
Bowen KJ; Kris-Etherton PM; Shearer GC; West SG; Reddivari L; Jones PJH
Prog Lipid Res; 2017 Jul; 67():1-15. PubMed ID: 28389247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
